CD300A

Across TCGA pan-cancer cohorts, CD300A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD300A data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD300A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CD300A expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where CD300A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.376	0.685	.002	48	view →
GBM	OS	Median	All	0.382	0.722	<.001	13	view →
CCRCC	DFS	Quartile	II,III,IV	0.838	0.378	.002	10	view →
LSCC	OS	Median	II,III,IV	0.602	0.959	.002	10	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD300A–PDAC (OS)

Open the PDAC breakdown →